![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
KA Berg, WP Clarke, Y Chen, BJ Ebersole, RD McKay and S Maayani
Department of Anesthesiology, Mount Sinai School of Medicine, City University of New York, New York 10029.
The effects of 5-hydroxytryptamine (5-HT)2A receptor activation on cAMP formation were studied in a cell line derived from embryonic rat cortex (A1A1). 5-HT (EC50 = 0.87 microM) amplified the amount of cAMP formed in response to 5'-N-ethylcarboxamidoadenosine (an adenosine A2 receptor agonist), cholera toxin, and forskolin after 15 min of coincubation in the presence of the phosphodiesterase inhibitor rolipram. This effect of 5-HT was blocked by 10 nM ketanserin as well as by 10 nM spiperone, indicating a response mediated by the 5-HT2A receptor subtype. Similarly, cAMP accumulation was enhanced by coincubation with the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) and the calcium ionophore A23187. After exposure to PMA for 24 hr (PKC- depleted cells), 5-HT and A23187 still enhanced cAMP formed in response to forskolin and 5'-N-ethylcarboxamidoadenosine, whereas the amplifying effects of PMA were abolished. Analysis by Western blots and PKC activity measurements revealed that, of three PKC isoforms detected in A1A1 cells (alpha, delta, and epsilon), only the calcium-independent isoform PKC-epsilon remained in membrane fractions after long term PMA treatment. In PKC-depleted cells, 5-HT-mediated amplification was greatly reduced after treatment with the calcium chelator 1,2-bis(o- aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (acetoxymethyl)-ester or the calmodulin antagonists calmidazolium and N-(6-aminohexyl)-5-chloro- 1-napthalenesulfonamide hydrochloride. In addition, 5-HT-mediated amplification of cAMP accumulation was reduced by the PKC inhibitor staurosporine in normal cells but was unaffected in PKC-depleted cells. In conclusion, these data suggest that 5-HT2A receptor activation can amplify cAMP formation in A1A1 cells by two distinct pathways coupled to the hydrolysis of inositol phosphates, i.e., PKC and calcium/calmodulin.
This article has been cited by other articles:
|
|
 |
|
  J. Shi, B. Zemaitaitis, and N. A. Muma Phosphorylation of G{alpha}11 Protein Contributes to Agonist-Induced Desensitization of 5-HT2A Receptor Signaling Mol. Pharmacol., January 1, 2007; 71(1): 303 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Turner and J. R. Raymond Interaction of Calmodulin with the Serotonin 5-Hydroxytryptamine2A Receptor: A PUTATIVE REGULATOR OF G PROTEIN COUPLING AND RECEPTOR PHOSPHORYLATION BY PROTEIN KINASE C J. Biol. Chem., September 2, 2005; 280(35): 30741 - 30750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Silver, N. V. Nucci, A. R. Root, K. L. Reed, and S. A. Sower Cloning and Characterization of a Functional Type II Gonadotropin-Releasing Hormone Receptor with a Lengthy Carboxy-Terminal Tail from an Ancestral Vertebrate, the Sea Lamprey Endocrinology, August 1, 2005; 146(8): 3351 - 3361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Berg, K. L. J. Evans, J. D. Cropper, and W. P. Clarke Temporal Regulation of Agonist Efficacy at 5-Hydroxytryptamine (5-HT)1A and 5-HT1B Receptors J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 200 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Kurrasch-Orbaugh, V. J. Watts, E. L. Barker, and D. E. Nichols Serotonin 5-Hydroxytryptamine2A Receptor-Coupled Phospholipase C and Phospholipase A2 Signaling Pathways Have Different Receptor Reserves J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 229 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Ott, B. E. Troskie, R. W. Roeske, N. Illing, C. A. Flanagan, and R. P. Millar Two Mutations in Extracellular Loop 2 of the Human GnRH Receptor Convert an Antagonist to an Agonist Mol. Endocrinol., May 1, 2002; 16(5): 1079 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Okubo, S. Nagata, R. Ko, H. Kataoka, Y. Yoshiura, H. Mitani, M. Kondo, K. Naruse, A. Shima, and K. Aida Identification and Characterization of Two Distinct GnRH Receptor Subtypes in a Teleost, the Medaka Oryzias latipes Endocrinology, November 1, 2001; 142(11): 4729 - 4739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. J. Evans, J. D. Cropper, K. A. Berg, and W. P. Clarke Mechanisms of Regulation of Agonist Efficacy at the 5-HT1A Receptor by Phospholipid-Derived Signaling Components J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1025 - 1035. [Abstract] [Full Text]
|
|
|
|
|
|
B. E. Troskie, J. P. Hapgood, R. P. Millar, and N. Illing Complementary Deoxyribonucleic Acid Cloning, Gene Expression, and Ligand Selectivity of a Novel Gonadotropin-Releasing Hormone Receptor Expressed in the Pituitary and Midbrain of Xenopus laevis Endocrinology, May 1, 2000; 141(5): 1764 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Berg, B. D. Stout, J. D. Cropper, S. Maayani, and W. P. Clarke Novel Actions of Inverse Agonists on 5-HT2C Receptor Systems Mol. Pharmacol., May 1, 1999; 55(5): 863 - 872. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Illing, B. E. Troskie, C. S. Nahorniak, J. P. Hapgood, R. E. Peter, and R. P. Millar Two gonadotropin-releasing hormone receptor subtypes with distinct ligand selectivity and differential distribution in brain and pituitary in the goldfish (Carassius auratus) PNAS, March 2, 1999; 96(5): 2526 - 2531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Berg, S. Maayani, J. Goldfarb, C. Scaramellini, P. Leff, and W. P. Clarke Effector Pathway-Dependent Relative Efficacy at Serotonin Type 2A and 2C Receptors: Evidence for Agonist-Directed Trafficking of Receptor Stimulus Mol. Pharmacol., July 1, 1998; 54(1): 94 - 104. [Abstract] [Full Text]
|
|
|
|
|
|
C. C. Gerhardt, R. A. Bakker, G. J. Piek, R. J. Planta, E. Vreugdenhil, J. E. Leysen, and H. Van Heerikhuizen Molecular Cloning and Pharmacological Characterization of a Molluscan Octopamine Receptor Mol. Pharmacol., February 1, 1997; 51(2): 293 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Sealfon, L. Chi, B. J. Ebersole, V. Rodic, D. Zhang, J. A. Ballesteros, and H. Weinstein Related Contribution of Specific Helix 2 and 7 Residues to Conformational Activation of the Serotonin 5-HT[IMAGE] Receptor J. Biol. Chem., July 14, 1995; 270(28): 16683 - 16688. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
